Pediatrix Medical Group, Inc. (MD)
(Delayed Data from NYSE)
$7.68 USD
0.00 (0.00%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $7.68 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.68 USD
0.00 (0.00%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $7.68 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth D Momentum D VGM
Zacks News
Implied Volatility Surging for Pediatrix Medical (MD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Pediatrix Medical (MD) stock based on the movements in the options market lately.
Implied Volatility Surging for Pediatrix Medical (MD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Pediatrix Medical (MD) stock based on the movements in the options market lately.
Why Is Pediatrix Medical Group (MD) Down 15.9% Since Last Earnings Report?
by Zacks Equity Research
Pediatrix Medical Group (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pediatrix (MD) Q1 Earnings Beat on Hospital Contract Fees
by Zacks Equity Research
Pediatrix's (MD) Q1 results benefit from higher same-unit revenues, resulting from growing patient volumes, partly offset by high costs. It continues to expect 2024 adjusted EBITDA within $200-$220 million.
Compared to Estimates, Pediatrix Medical Group (MD) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Pediatrix Medical Group (MD) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Life Time Group Holdings, Inc. (LTH) Q1 Earnings Miss Estimates
by Zacks Equity Research
Life Time Group Holdings (LTH) delivered earnings and revenue surprises of -6.25% and 1.39%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ICON (ICLR) Up 7.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
ICON (ICLR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pediatrix Medical Group, Inc. (MD) Up 11% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Pediatrix Medical Group, Inc. (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pediatrix's (MD) Q4 Earnings Miss Due to Soft Patient Volumes
by Zacks Equity Research
Pediatrix's (MD) Q4 results were hit by an increase in overall cost level resulting from higher same-unit clinical compensation costs. Yet, an impressive 2024 adjusted EBITDA guidance is likely to provide relief to investors.
Pediatrix Medical Group (MD) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Pediatrix Medical Group (MD) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Will High Expenses Ail Pediatrix Medical's (MD) Q4 Earnings?
by Zacks Equity Research
Pediatrix Medical's (MD) Q4 results are likely to be hurt by an increase in practice salaries and benefits expense as well as softer patient volumes, partly offset by same-unit pricing growth.
Pediatrix (MD) Q3 Earnings Miss on High Costs, Shares Down 12%
by Zacks Equity Research
Pediatrix's (MD) third-quarter results suffer from the decline in same-unit revenues attributable to patient volume. Management currently expects 2023 adjusted EBITDA to be within $200-$210 million.
Pediatrix Medical Group (MD) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Pediatrix Medical Group (MD) delivered earnings and revenue surprises of -25.58% and 0.43%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Establishment Labs Holdings Inc. (ESTA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Establishment Labs Holdings Inc. (ESTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Revvity (RVTY) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Revvity (RVTY) delivered earnings and revenue surprises of -0.84% and 3.10%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Pediatrix Medical Group (MD) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Pediatrix Medical Group (MD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MD or DOCS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MD vs. DOCS: Which Stock Is the Better Value Option?
Why Investors Are Retaining Pediatrix Medical (MD) Stock Now
by Zacks Equity Research
Pediatrix Medical's (MD) rising net patient service revenues will likely benefit its top line.
Pediatrix Medical Group (MD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Pediatrix Medical Group (MD) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Pediatrix (MD) Q2 Earnings Meet Estimates, Revenues Up Y/Y
by Zacks Equity Research
Pediatrix (MD) reiterates adjusted EBITDA guidance in the range of $235-$245 million for 2023 compared with $241 million in 2022.
Pediatrix Medical Group (MD) Meets Q2 Earnings Estimates
by Zacks Equity Research
Pediatrix Medical Group (MD) delivered earnings and revenue surprises of 0% and 1.23%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
MD vs. PGNY: Which Stock Is the Better Value Option?
by Zacks Equity Research
MD vs. PGNY: Which Stock Is the Better Value Option?
Strength Seen in Surgery Partners (SGRY): Can Its 5.0% Jump Turn into More Strength?
by Zacks Equity Research
Surgery Partners (SGRY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Why Is Pediatrix Medical Group (MD) Down 4.9% Since Last Earnings Report?
by Zacks Equity Research
Pediatrix Medical Group (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pediatrix (MD) Down 4.2% Despite Q1 Earnings & Revenue Beat
by Zacks Equity Research
Investors are likely concerned about Pediatrix's (MD) lower enrollment in commercial insurance programs, escalating practice salaries and benefits and net borrowings.